Davita Inc vs TeraWulf Inc — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while TeraWulf Inc trades at $17.21 (market cap $8.08B). The key difference: Davita Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| DVA | WULF | |
|---|---|---|
Market Cap | $11.72B | $8.08B |
Sector | Health | Technology |
52-Week High | $240.96 | $28.98 |
52-Week Low | $103.87 | $5.24 |
Enterprise Value | $24.44B | $10.70B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
TeraWulf (WULF) trades at $17.08, down 3.04% on the day, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $165M but a significant net loss of -$1.9B, reflecting a profit margin of -1,179.95%. Despite negative profitability metrics, all 14 analysts maintain Buy ratings with a $38 consensus price target, citing growth potential from AI infrastructure expansion including a major Anthropic lease.
The stock presents a high-risk, high-reward opportunity with strong Wall Street conviction despite fundamental challenges. Key catalysts include the AI pivot and capacity expansion, but investors face substantial execution risks, capital requirements, and ongoing losses that could pressure the stock near-term.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →